Ulcerative Colitis Study Begins Treating 1st Pediatric Patient via Fecal Microbial Transplant

Ulcerative Colitis Study Begins Treating 1st Pediatric Patient via Fecal Microbial Transplant
Rebiotix Inc., a biotechnology company in Roseville, Minnesota, and McMaster Children’s Hospital, a pediatric academic health sciences center in Ontario, Canada, recently announced that the first patient in the PediFETCh (Pediatric FEcal microbial Transplant for ulcerative Colitis) clinical trial has started treatment. Ulcerative colitis is an inflammatory bowel disease (IBD) characterized by chronic inflammation in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *